格隆汇4月17日丨复宏汉霖(02696.HK)宣布,近日,一项HLX22(重组人源化抗HER2单克隆抗体注射液)("HLX22")联合德曲妥珠单抗治疗HER2低表达HR阳性的局部晚期或转移性乳腺癌的2期临床研究于中国大陆完成首例患者给药。 临床试验设计及目的 本研究是一项多中心的2期临床研究,旨在评估HLX22联合德曲妥珠单抗治疗经标准治疗后疾病进展或不可耐受毒性反应的,HER2低表达HR阳性的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.